Literature DB >> 17237698

Erlotinib-associated trichomegaly.

Katherine Lane1, Scott M Goldstein.   

Abstract

A 70-year-old woman presented with a corneal ulcer resulting from aberrant and exuberant eyelash growth. She had recently been diagnosed with recurrent non-small-cell lung cancer for which she had begun a chemotherapeutic regimen that included erlotinib HCl. After several months of treatment, she noted the onset of escalating ocular irritation, which culminated in her presentation. Examination of her ocular adnexa revealed coarse, brittle, irregular aberrant eyelash growth. She has been successfully treated with regular epilation and eyelash trimming and has remained symptom free.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237698     DOI: 10.1097/IOP.0b013e31802d9802

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  12 in total

Review 1.  Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.

Authors:  Vivian T Yin; Helen Merritt; Bita Esmaeli
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

2.  Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.

Authors:  Shan-Bing Wang; Kai-Jian Lei; Jia-Pei Liu; Yu-Ming Jia
Journal:  Oncol Lett       Date:  2015-05-26       Impact factor: 2.967

3.  A case of acquired trichomegaly following treatment with erlotinib.

Authors:  Fiona Jazayeri; Raman Malhotra
Journal:  BMJ Case Rep       Date:  2009-05-20

Review 4.  Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.

Authors:  Vivian T Yin; Margaret L Pfeiffer; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2013 Mar-Apr       Impact factor: 1.746

5.  Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

Authors:  Durga S Borkar; Mario E Lacouture; Surendra Basti
Journal:  Support Care Cancer       Date:  2012-11-15       Impact factor: 3.603

Review 6.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

7.  Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.

Authors:  Jeeyun Ahn; Won Ryang Wee; Jin Hak Lee; Joon Young Hyon
Journal:  Korean J Ophthalmol       Date:  2011-09-20

8.  Trichomegaly of eyelashes after treatment with erlotinib in carcinoma pancreas.

Authors:  Varun Goel; Shubhra Raina; D Chandragouda; Sajjan Singh; Vineet Talwar; Nivedita Patnaik
Journal:  Int J Trichology       Date:  2014-01

9.  Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review.

Authors:  Hua Zheng; Hongmei Zhang; Tongmei Zhang; Qunhui Wang; Fanbin Hu; Baolan Li
Journal:  Exp Ther Med       Date:  2016-06-16       Impact factor: 2.447

10.  Erlotinib induced trichomegaly of the eyelashes.

Authors:  Sang-Hoon Jeon; Jeong-Seon Ryu; Gwang-Seong Choi; Jung-Soo Kim; Hea-Yoon Kwon; Min-Su Kim; Hae-Seong Nam; Jae-Hwa Cho; Seung-Min Kwak; Hong Lyeol Lee; Hyun-Jung Kim; Geun-Jeong Hong
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.